{
  "url": "https://www.webmd.com/cancer/multiple-myeloma/tac-t-cell-therapy-multiple-myeloma",
  "title": "TAC T-Cell Therapy for Multiple Myeloma",
  "slug": "tac-t-cell-therapy-multiple-myeloma",
  "published_date": "2025-08-16",
  "first_letter": "T",
  "author": "Rachel Reiff Ellis",
  "medically_reviewed_by": "Laura J. Martin, MD",
  "read_time": "4 min read",
  "sections": [
    {
      "heading": null,
      "content": [
        "TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would be a safer and more effective immunotherapy than another type of this treatment called CAR T-cell therapy. Immunotherapy is cancer treatment that uses your own immune system to lock onto and destroy things such as bacteria, viruses, and cancer.",
        "The TAC molecule uses the natural biology of specific immune cells in your body called T cells to recognize and destroy cancer cells. Researchers first developed it as a possible treatment for HER2-positive breast cancers. HER2 is an antigen on breast cancer cells -- a protein on the cell’s surface that tells your immune system it’s a foreign substance that needs to be destroyed.",
        "Clinical trials on TAC therapy for HER2-positive breast cancer started in April 2021 and are ongoing. Biotech companies are now looking at developing TAC T-cell studies for multiple myeloma as well."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would be a safer and more effective immunotherapy than another type of this treatment called CAR T-cell therapy. Immunotherapy is cancer treatment that uses your own immune system to lock onto and destroy things such as bacteria, viruses, and cancer.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "The TAC molecule uses the natural biology of specific immune cells in your body called T cells to recognize and destroy cancer cells. Researchers first developed it as a possible treatment for HER2-positive breast cancers. HER2 is an antigen on breast cancer cells -- a protein on the cell’s surface that tells your immune system it’s a foreign substance that needs to be destroyed.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "Clinical trials on TAC therapy for HER2-positive breast cancer started in April 2021 and are ongoing. Biotech companies are now looking at developing TAC T-cell studies for multiple myeloma as well.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "Therapies Related to TAC T-Cell Therapy",
      "content": [
        "To understand TAC therapy, it’s helpful to know more about other T-cell therapies that are related to it. These therapies all involve T cells modified in a lab, but the way they work to attack cancer cells is slightly different.",
        "CAR T-cell therapy. CAR stands for chimeric antigen receptor. “Chimeric” means that the protein receptor has a different genetic code than the tissues in the rest of your body. A doctor takes a blood sample from your body through an IV and sends it to a lab. Technicians genetically alter the T cells in your blood sample so that they express a chimeric antigen receptor on their cell surface.",
        "After the lab multiplies these altered T cells for a few weeks, your doctor puts them back into your bloodstream. The added receptor on the T cell’s surface helps your immune system “see” specific proteins on the surface of cancer cells. In multiple myeloma cells, this is a protein called BCMA. The modified receptor and BCMA proteins fit together like a key and a lock. Once they bind, the T cell destroys the cancer cell."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "To understand TAC therapy, it’s helpful to know more about other T-cell therapies that are related to it. These therapies all involve T cells modified in a lab, but the way they work to attack cancer cells is slightly different.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "CAR T-cell therapy. CAR stands for chimeric antigen receptor. “Chimeric” means that the protein receptor has a different genetic code than the tissues in the rest of your body. A doctor takes a blood sample from your body through an IV and sends it to a lab. Technicians genetically alter the T cells in your blood sample so that they express a chimeric antigen receptor on their cell surface.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "After the lab multiplies these altered T cells for a few weeks, your doctor puts them back into your bloodstream. The added receptor on the T cell’s surface helps your immune system “see” specific proteins on the surface of cancer cells. In multiple myeloma cells, this is a protein called BCMA. The modified receptor and BCMA proteins fit together like a key and a lock. Once they bind, the T cell destroys the cancer cell.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would be a safer and more effective immunotherapy than another type of this treatment called CAR T-cell therapy. Immunotherapy is cancer treatment that uses your own immune system to lock onto and destroy things such as bacteria, viruses, and cancer.",
        "The TAC molecule uses the natural biology of specific immune cells in your body called T cells to recognize and destroy cancer cells. Researchers first developed it as a possible treatment for HER2-positive breast cancers. HER2 is an antigen on breast cancer cells -- a protein on the cell’s surface that tells your immune system it’s a foreign substance that needs to be destroyed.",
        "Clinical trials on TAC therapy for HER2-positive breast cancer started in April 2021 and are ongoing. Biotech companies are now looking at developing TAC T-cell studies for multiple myeloma as well."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would be a safer and more effective immunotherapy than another type of this treatment called CAR T-cell therapy. Immunotherapy is cancer treatment that uses your own immune system to lock onto and destroy things such as bacteria, viruses, and cancer.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "The TAC molecule uses the natural biology of specific immune cells in your body called T cells to recognize and destroy cancer cells. Researchers first developed it as a possible treatment for HER2-positive breast cancers. HER2 is an antigen on breast cancer cells -- a protein on the cell’s surface that tells your immune system it’s a foreign substance that needs to be destroyed.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "Clinical trials on TAC therapy for HER2-positive breast cancer started in April 2021 and are ongoing. Biotech companies are now looking at developing TAC T-cell studies for multiple myeloma as well.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "Therapies Related to TAC T-Cell Therapy",
      "content": [
        "To understand TAC therapy, it’s helpful to know more about other T-cell therapies that are related to it. These therapies all involve T cells modified in a lab, but the way they work to attack cancer cells is slightly different.",
        "CAR T-cell therapy. CAR stands for chimeric antigen receptor. “Chimeric” means that the protein receptor has a different genetic code than the tissues in the rest of your body. A doctor takes a blood sample from your body through an IV and sends it to a lab. Technicians genetically alter the T cells in your blood sample so that they express a chimeric antigen receptor on their cell surface.",
        "After the lab multiplies these altered T cells for a few weeks, your doctor puts them back into your bloodstream. The added receptor on the T cell’s surface helps your immune system “see” specific proteins on the surface of cancer cells. In multiple myeloma cells, this is a protein called BCMA. The modified receptor and BCMA proteins fit together like a key and a lock. Once they bind, the T cell destroys the cancer cell."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "To understand TAC therapy, it’s helpful to know more about other T-cell therapies that are related to it. These therapies all involve T cells modified in a lab, but the way they work to attack cancer cells is slightly different.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "CAR T-cell therapy. CAR stands for chimeric antigen receptor. “Chimeric” means that the protein receptor has a different genetic code than the tissues in the rest of your body. A doctor takes a blood sample from your body through an IV and sends it to a lab. Technicians genetically alter the T cells in your blood sample so that they express a chimeric antigen receptor on their cell surface.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "After the lab multiplies these altered T cells for a few weeks, your doctor puts them back into your bloodstream. The added receptor on the T cell’s surface helps your immune system “see” specific proteins on the surface of cancer cells. In multiple myeloma cells, this is a protein called BCMA. The modified receptor and BCMA proteins fit together like a key and a lock. Once they bind, the T cell destroys the cancer cell.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "The FDA approved the first CAR T-cell therapy for multiple myeloma in March 2021 and a second in February 2022. Studies show these treatments can keep this cancer in check for at least a year.",
        "The most recently approved CAR T-cell drug is ciltacabtagene autoleucel ( Carvykti ). For people taking it, the response rate is 85%. This means almost all people taking it saw at least some reduction in the cancer in their bodies. For most people, this response lasted almost 2 years.",
        "But these drugs also come with possible serious or even life-threatening side effects. They are also costly to make and can take up to a month to be ready for people who need them. This is because they are made specifically for the receptors on your personal cancer cells. Doctors continue to study improvements and additions to CAR T-cell therapy.",
        "TCR therapy. TCR (T-cell receptor) therapy is also a T-cell immunotherapy. Like CAR T-cell therapy, it attaches a lab-made receptor to recognize surface proteins on cancer cells. But it also uses a T cell’s natural mechanisms to find and destroy them. This means it can be more specific about which cells to target."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "The FDA approved the first CAR T-cell therapy for multiple myeloma in March 2021 and a second in February 2022. Studies show these treatments can keep this cancer in check for at least a year.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "The most recently approved CAR T-cell drug is ciltacabtagene autoleucel ( Carvykti ). For people taking it, the response rate is 85%. This means almost all people taking it saw at least some reduction in the cancer in their bodies. For most people, this response lasted almost 2 years.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "But these drugs also come with possible serious or even life-threatening side effects. They are also costly to make and can take up to a month to be ready for people who need them. This is because they are made specifically for the receptors on your personal cancer cells. Doctors continue to study improvements and additions to CAR T-cell therapy.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "TCR therapy. TCR (T-cell receptor) therapy is also a T-cell immunotherapy. Like CAR T-cell therapy, it attaches a lab-made receptor to recognize surface proteins on cancer cells. But it also uses a T cell’s natural mechanisms to find and destroy them. This means it can be more specific about which cells to target.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "Tumor cell proteins can look a lot like normal cell surface proteins, and often CAR T-cell therapies target these normal cells alongside cancer cells. This causes many of the serious side effects for people treating solid tumors with CAR T-cell therapy.",
        "But in studies, TCR therapy has worked well in destroying blood, lung, breast, prostate, colon, bone, skin, kidney , ovarian, and cervical cancer cells while avoiding healthy cells. This means fewer side effects. Because of this, researchers began to explore and build on TCR mechanisms to create TAC T-cell therapy."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "Tumor cell proteins can look a lot like normal cell surface proteins, and often CAR T-cell therapies target these normal cells alongside cancer cells. This causes many of the serious side effects for people treating solid tumors with CAR T-cell therapy.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "But in studies, TCR therapy has worked well in destroying blood, lung, breast, prostate, colon, bone, skin, kidney , ovarian, and cervical cancer cells while avoiding healthy cells. This means fewer side effects. Because of this, researchers began to explore and build on TCR mechanisms to create TAC T-cell therapy.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "How TAC T-Cell Therapy Works",
      "content": [
        "TAC T-cell therapy is a type of TCR therapy. (TAC stands for T-cell antigen coupler.) Doctors take a sample of your blood and send it to a lab where technicians add receptors to your T cells. They do this using a gene called the TAC transgene. This gene tells the cells to express the TAC molecule across the surface of the cell."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "TAC T-cell therapy is a type of TCR therapy. (TAC stands for T-cell antigen coupler.) Doctors take a sample of your blood and send it to a lab where technicians add receptors to your T cells. They do this using a gene called the TAC transgene. This gene tells the cells to express the TAC molecule across the surface of the cell.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "The FDA approved the first CAR T-cell therapy for multiple myeloma in March 2021 and a second in February 2022. Studies show these treatments can keep this cancer in check for at least a year.",
        "The most recently approved CAR T-cell drug is ciltacabtagene autoleucel ( Carvykti ). For people taking it, the response rate is 85%. This means almost all people taking it saw at least some reduction in the cancer in their bodies. For most people, this response lasted almost 2 years.",
        "But these drugs also come with possible serious or even life-threatening side effects. They are also costly to make and can take up to a month to be ready for people who need them. This is because they are made specifically for the receptors on your personal cancer cells. Doctors continue to study improvements and additions to CAR T-cell therapy.",
        "TCR therapy. TCR (T-cell receptor) therapy is also a T-cell immunotherapy. Like CAR T-cell therapy, it attaches a lab-made receptor to recognize surface proteins on cancer cells. But it also uses a T cell’s natural mechanisms to find and destroy them. This means it can be more specific about which cells to target."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "The FDA approved the first CAR T-cell therapy for multiple myeloma in March 2021 and a second in February 2022. Studies show these treatments can keep this cancer in check for at least a year.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "The most recently approved CAR T-cell drug is ciltacabtagene autoleucel ( Carvykti ). For people taking it, the response rate is 85%. This means almost all people taking it saw at least some reduction in the cancer in their bodies. For most people, this response lasted almost 2 years.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "But these drugs also come with possible serious or even life-threatening side effects. They are also costly to make and can take up to a month to be ready for people who need them. This is because they are made specifically for the receptors on your personal cancer cells. Doctors continue to study improvements and additions to CAR T-cell therapy.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "TCR therapy. TCR (T-cell receptor) therapy is also a T-cell immunotherapy. Like CAR T-cell therapy, it attaches a lab-made receptor to recognize surface proteins on cancer cells. But it also uses a T cell’s natural mechanisms to find and destroy them. This means it can be more specific about which cells to target.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "Tumor cell proteins can look a lot like normal cell surface proteins, and often CAR T-cell therapies target these normal cells alongside cancer cells. This causes many of the serious side effects for people treating solid tumors with CAR T-cell therapy.",
        "But in studies, TCR therapy has worked well in destroying blood, lung, breast, prostate, colon, bone, skin, kidney , ovarian, and cervical cancer cells while avoiding healthy cells. This means fewer side effects. Because of this, researchers began to explore and build on TCR mechanisms to create TAC T-cell therapy."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "Tumor cell proteins can look a lot like normal cell surface proteins, and often CAR T-cell therapies target these normal cells alongside cancer cells. This causes many of the serious side effects for people treating solid tumors with CAR T-cell therapy.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "But in studies, TCR therapy has worked well in destroying blood, lung, breast, prostate, colon, bone, skin, kidney , ovarian, and cervical cancer cells while avoiding healthy cells. This means fewer side effects. Because of this, researchers began to explore and build on TCR mechanisms to create TAC T-cell therapy.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "How TAC T-Cell Therapy Works",
      "content": [
        "TAC T-cell therapy is a type of TCR therapy. (TAC stands for T-cell antigen coupler.) Doctors take a sample of your blood and send it to a lab where technicians add receptors to your T cells. They do this using a gene called the TAC transgene. This gene tells the cells to express the TAC molecule across the surface of the cell."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "TAC T-cell therapy is a type of TCR therapy. (TAC stands for T-cell antigen coupler.) Doctors take a sample of your blood and send it to a lab where technicians add receptors to your T cells. They do this using a gene called the TAC transgene. This gene tells the cells to express the TAC molecule across the surface of the cell.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "A TAC molecule can’t signal a cell on its own, but it can redirect them to use their natural TCR mechanism to target a cancer cell and destroy it. The T cell does this by recruiting small proteins called cytokines. They signal to enzymes that tell the cancer cell to die.",
        "Because TAC molecules use a T cell’s natural mechanism, it lowers the chance that the T cells will keep attacking cells and cause problems with healthy cells. Researchers can also make custom TAC receptors to target different tumor types. These work for both solid tumors and blood cancers such as multiple myeloma ."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "A TAC molecule can’t signal a cell on its own, but it can redirect them to use their natural TCR mechanism to target a cancer cell and destroy it. The T cell does this by recruiting small proteins called cytokines. They signal to enzymes that tell the cancer cell to die.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "Because TAC molecules use a T cell’s natural mechanism, it lowers the chance that the T cells will keep attacking cells and cause problems with healthy cells. Researchers can also make custom TAC receptors to target different tumor types. These work for both solid tumors and blood cancers such as multiple myeloma .",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "Who Might Get TAC T-Cell Therapy?",
      "content": [
        "When you have multiple myeloma that comes back (relapses), typically the chances of treating it successfully go down. Doctors turn to CAR T-cell therapy for people who have already received several (typically at least four) other types of treatment for their multiple myeloma.",
        "By the time you qualify for a CAR T-cell therapy, your immune system has been working hard. Some doctors wonder whether it makes sense to try these therapies earlier in treatment, even as a first option. This would potentially mean a more robust immune system that might be able to work better with the immunotherapy drugs."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "When you have multiple myeloma that comes back (relapses), typically the chances of treating it successfully go down. Doctors turn to CAR T-cell therapy for people who have already received several (typically at least four) other types of treatment for their multiple myeloma.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "By the time you qualify for a CAR T-cell therapy, your immune system has been working hard. Some doctors wonder whether it makes sense to try these therapies earlier in treatment, even as a first option. This would potentially mean a more robust immune system that might be able to work better with the immunotherapy drugs.",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": null,
      "content": [
        "A TAC molecule can’t signal a cell on its own, but it can redirect them to use their natural TCR mechanism to target a cancer cell and destroy it. The T cell does this by recruiting small proteins called cytokines. They signal to enzymes that tell the cancer cell to die.",
        "Because TAC molecules use a T cell’s natural mechanism, it lowers the chance that the T cells will keep attacking cells and cause problems with healthy cells. Researchers can also make custom TAC receptors to target different tumor types. These work for both solid tumors and blood cancers such as multiple myeloma ."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "A TAC molecule can’t signal a cell on its own, but it can redirect them to use their natural TCR mechanism to target a cancer cell and destroy it. The T cell does this by recruiting small proteins called cytokines. They signal to enzymes that tell the cancer cell to die.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "Because TAC molecules use a T cell’s natural mechanism, it lowers the chance that the T cells will keep attacking cells and cause problems with healthy cells. Researchers can also make custom TAC receptors to target different tumor types. These work for both solid tumors and blood cancers such as multiple myeloma .",
          "associated_bullets": null
        }
      ]
    },
    {
      "heading": "Who Might Get TAC T-Cell Therapy?",
      "content": [
        "When you have multiple myeloma that comes back (relapses), typically the chances of treating it successfully go down. Doctors turn to CAR T-cell therapy for people who have already received several (typically at least four) other types of treatment for their multiple myeloma.",
        "By the time you qualify for a CAR T-cell therapy, your immune system has been working hard. Some doctors wonder whether it makes sense to try these therapies earlier in treatment, even as a first option. This would potentially mean a more robust immune system that might be able to work better with the immunotherapy drugs."
      ],
      "bullets": null,
      "content_blocks": [
        {
          "type": "paragraph",
          "text": "When you have multiple myeloma that comes back (relapses), typically the chances of treating it successfully go down. Doctors turn to CAR T-cell therapy for people who have already received several (typically at least four) other types of treatment for their multiple myeloma.",
          "associated_bullets": null
        },
        {
          "type": "paragraph",
          "text": "By the time you qualify for a CAR T-cell therapy, your immune system has been working hard. Some doctors wonder whether it makes sense to try these therapies earlier in treatment, even as a first option. This would potentially mean a more robust immune system that might be able to work better with the immunotherapy drugs.",
          "associated_bullets": null
        }
      ]
    }
  ],
  "pdfs": [],
  "images": [
    "https://img.lb.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/logos/webmd/web/webmd-logo-fb.jpg",
    "https://img.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/logos/webmd/web/webmd_logo_white.svg",
    "https://img.lb.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/articles/biographies/rachel-reiff-ellis-382x382.jpg?resize=51px:51px&output-quality=75",
    "https://img.lb.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/articles/biographies/avatar_placeholder.jpg?resize=51px:51px&output-quality=75",
    "https://img.lb.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/article_thumbnails/hpt_toc_redesign/more_on/MoreOn_BreastCancer.jpg?resize=300px:*&output-quality=75",
    "https://img.lb.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/article_thumbnails/hpt_toc_redesign/hpt_toc_redesign_illustrations/1500x1500_diagnosis_and_test_option_3.jpg?resize=500px:*&output-quality=75",
    "https://privacy-policy.truste.com/privacy-seal/seal?rid=07326333-3522-463d-81bf-f00fd7171fff",
    "https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/layout/shared/tag-registered.png?resize=*:60px",
    "https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/oncology/1/footer-images/ad-choice.png",
    "https://img.wbmdstatic.com/vim/live/webmd/consumer_assets/site_images/oncology/1/images/webmd-logo-white.svg",
    "https://sb.scorecardresearch.com/p?c1=2&c2=6035829&cv=3.6&cj=1"
  ],
  "related_links": [],
  "sources": [
    "Blood: “T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies.”",
    "Cytotherapy : “Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma.”",
    "ClinicalTrials.gov: “TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2).”",
    "Multiple Myeloma Research Foundation: “MIF Invests in Triumvira Immunologics to Advance Novel (TAC)-T Cell Therapy for the Treatment of Multiple Myeloma.”",
    "Moffitt Cancer Center: “T-Cell Receptor (TCR) Therapy.”",
    "American Cancer Society: “CAR T-cell Therapy for Multiple Myeloma.”",
    "National Cancer Institute: “Chimeric antigen receptor,” “Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma,” “Chimeric.”",
    "FDA: “FDA approves idecabtagene vicleucel for multiple myeloma.”",
    "American Society of Hematology: “1433 Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors.”",
    "Frontiers in Immunology: “ Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.”",
    "Nature Communications : “The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.”"
  ],
  "meta_description": "TAC T-cell therapy shows promise for treating breast cancer. Could this new immunotherapy be on the horizon for treating multiple myeloma?",
  "canonical_url": "https://www.webmd.com/cancer/multiple-myeloma/tac-t-cell-therapy-multiple-myeloma",
  "tags": [
    "Health Topics",
    "WebMD"
  ],
  "scrape_timestamp_utc": "2026-01-23T03:26:08.951025Z"
}